HAEKD Stock Overview
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
HAEMATO AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €27.40 |
52 Week High | €0 |
52 Week Low | €0 |
Beta | 1.3 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | -48.30% |
Change since IPO | -50.45% |
Recent News & Updates
Recent updates
Shareholder Returns
HAEKD | GB Healthcare | GB Market | |
---|---|---|---|
7D | 0% | 0.5% | 2.2% |
1Y | n/a | -21.8% | 3.7% |
Return vs Industry: Insufficient data to determine how HAEKD performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how HAEKD performed against the UK Market.
Price Volatility
HAEKD volatility | |
---|---|
HAEKD Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: HAEKD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HAEKD's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 76 | Patrick Brenske | https://www.haemato.ag |
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements.
HAEMATO AG Fundamentals Summary
HAEKD fundamental statistics | |
---|---|
Market cap | €111.87m |
Earnings (TTM) | €9.61m |
Revenue (TTM) | €260.81m |
11.6x
P/E Ratio0.4x
P/S RatioIs HAEKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HAEKD income statement (TTM) | |
---|---|
Revenue | €260.81m |
Cost of Revenue | €241.08m |
Gross Profit | €19.73m |
Other Expenses | €10.12m |
Earnings | €9.61m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.84 |
Gross Margin | 7.56% |
Net Profit Margin | 3.68% |
Debt/Equity Ratio | 0.2% |
How did HAEKD perform over the long term?
See historical performance and comparison